A Phase 3 interventional study of F-18-PSMA-1007 and F-18-Fluorocholine in Prostate Cancer and Prostate Cancer Recurrent, sponsored by ABX advanced biochemical compounds GmbH. Completed at 6 sites in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-29.
Sponsored by ABX advanced biochemical compounds GmbH · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 509 studies in Prostatic Neoplasms with a site in France — 89 open to participants now, 154 under way, 50 of them phase 3. Prostatic Neoplasms · France.
Among the 509 studies in Prostatic Neoplasms with a site in France, this one is the 193rd largest by enrollment of the 405 interventional ones that give a count, is one of 27 that started in 2019, is one of 143 in phase 3, and was the 311th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →89 of the 509 studies in Prostatic Neoplasms with a site in France are open now. Recruiting first, the newest first:
AstraZeneca · Sites in France, United States, Austria and 18 more countries
Ages 18+ · Men only
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD · Sites in France, Germany, Italy and 2 more countries
Ages 18+ · Men only
Institut Cancerologie de l'Ouest · Sites in France
Ages 18+ · Men only
AstraZeneca · Sites in France, United States, Australia and 21 more countries
Ages 18+ · Men only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
509 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 106 · Phase 3 149 · Phase 4 12
First in 1996; this study’s year is marked. 27 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 185 across the 405 interventional studies, 183 across the 99 observational. Of the 322 that completed or were terminated, 104 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
234 of 509 have an industry lead sponsor. The 10 most frequent:
ABX advanced biochemical compounds GmbH is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
ABX advanced biochemical compounds GmbH has 3 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
36 of the studies in Prostatic Neoplasms with a site in France that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT06551324Phase 3PfizerA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | 2027-02-28 |
| NCT06122584Phase 3ABX advanced biochemical compounds GmbHDiagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer | 2027-03 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
Add all 36 to your calendar (.ics) → With an account.
Among the 509 studies in Prostatic Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the diagnostic performance and safety of F-18-PSMA-1007 and F-18-Fluorocholine PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive F-18-PSMA-1007 PET/CT first, followed by F-18-Fluorocholine PET/CT.
Drug: F-18-PSMA-1007 · Drug: F-18-Fluorocholine
Patients will receive F-18-Fluorocholine PET/CT first, followed by F-18-PSMA-1007 PET/CT.
Drug: F-18-PSMA-1007 · Drug: F-18-Fluorocholine
Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
To compare detection rate of metastatic prostate cancer lesions of F-18-PSMA-1007 versus F-18-Fluorocholine
Time frame: Within 6 months after PET/CT
Ran from Mar 2019 to primary completion in Oct 2020, 19 months.
Of 127 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 19 months is below that.
Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PSMA-1007 F-18
ABX advanced biochemical compounds GmbH